<DOC>
	<DOCNO>NCT01497275</DOCNO>
	<brief_summary>The purpose study evaluate effect ( good bad ) combination ibritumomab tiuxetan ( Zevalin ) bortezomib ( Velcade ) patient relapsed/refractory mantle cell lymphoma . Zevalin monoclonal antibody combine radioactive substance give another monoclonal antibody call rituximab ( Rituxan ) . It work attach cancer cell release radiation damage cell . Both Zevalin Rituxan give study , along Velcade .</brief_summary>
	<brief_title>Zevalin Velcade Relapsed/Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description>This non-randomized , unblinded single arm Phase II trial evaluate combination yttrium90 ibritumomab tiuxetan bortezomib patient relapsed/refractory mantle cell lymphoma ( MCL ) . Standard hematology chemistry , image bone marrow biopsies do . Research test : 17cc blood collect screen , Day 8 OR 11 month 3 . Samples collect stored future analysis . These analysis may include limited measurement proteasome inhibition . No genetic study perform sample . Samples destroy end study . Primary Objective Estimate overall response rate ( CR + PR ) combination bortezomib ibritumomab tiuxetan patient relapsed/refractory mantle cell lymphoma . Secondary Objectives - Estimate progression free overall survival patient relapsed/refractory mantle cell lymphoma receive bortezomib ibritumomab tiuxetan . - Assess toxicity combination bortezomib ibritumomab tiuxetan patient relapsed/refractory MCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients relapse refractory Mantle Cell lymphoma measurable disease . Age &gt; 18 year old Expected survival &gt; /= 3 month Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 initiation study ( Appendix I ) . Laboratory test meet level specify protocol Patients must receive chemotherapy , radiation surgical resection malignancy within 3 week study initiation . However , receive nitrosurea mitomycin C enrol study 6 week therapy last receive . No limitation number prior therapies No prior radioimmunotherapy ( RIT ) Prior bortezomib allow Patient must fully recover toxicity associate prior surgery , radiation treatment , chemotherapy immunotherapy . No active , serious infection medical psychiatric illness likely interfere participation clinic trial No known HIV infection No active central nervous system ( CNS ) involvement Bone Marrow Involvement &gt; /= 25 % within 30 day initiation study treatment Pregnant breast feed No patient receive Granulocyte colonystimulating factor ( GCSF ) Granulocyte macrophage colonystimulating factor ( GMCSF ) within 14 day prior initiate protocol No patient major surgery within four week prior initiate protocol therapy No patient pleural effusion significant ascites</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>